Clinical Trial Update: Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder [Phase 2]

View source ↗

Summary

Phase 2 study update on brigimadlin (BI 907828) in biliary tract cancer, pancreatic cancer, lung cancer, and bladder cancer; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Cholangiocarcinoma
• Lung Cancer
• Pancreatic Cancer

Drugs mentioned

• brigimadlin (brigimadlin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pancreatic Neoplasms, Solid Tumors | Phase 2 | Status: COMPLETED